SCHEMBL2851218

SCHEMBL2851218

C=C(C(=O)OCC)C(O)c1cc(-c2ccccc2)cnc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.62
MAPT P10636 4/20 0.39
ALDH1A1 P00352 4/20 0.39
DHODH Q02127 1/20 0.37
XPO1 O14980 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
LMNA P02545 2/20 0.37
GRIN2B Q13224 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 2/20 0.35
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2849396 0.88 CASP1 (0.53) CASP1MAPTALDH1A1TDP1LMNA
SCHEMBL2853110 0.87 CASP1 (0.44) CASP1MAPTALDH1A1TDP1NPSR1
SCHEMBL2855426 0.83 CASP1 (0.56) CASP1MAPTALDH1A1XPO1TDP1
SCHEMBL2853196 0.81 CASP1 (0.54) CASP1MAPTALDH1A1TDP1LMNA
SCHEMBL2851268 0.81 CASP1 (0.58) CASP1MAPTALDH1A1DHODHXPO1
SCHEMBL2849135 0.79 CASP1 (0.56) CASP1MAPTALDH1A1DHODHXPO1
SCHEMBL2853071 0.78 CASP1 (0.55) CASP1MAPTALDH1A1TDP1LMNA
SCHEMBL15917187 0.78 CASP1 (1.00) CASP1MAPTALDH1A1RAB9ATP53
SCHEMBL30425504 0.78 CASP1 (1.00) CASP1MAPTALDH1A1RAB9ATP53
SCHEMBL13500116 0.76 CASP1 (0.52) CASP1MAPTALDH1A1DHODHXPO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US claimed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP claimed
EP-1924558-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-05-28 EP claimed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US claimed
WO-2007032016-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO claimed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP disclosed
EP-1924558-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-05-28 EP disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
WO-2007032016-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof HBS1L, SSBP1, QARS1 CASP1 931/4885MAPT 3203/4885ALDH1A1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.